VCYT
Veracyte Inc

1,245
Mkt Cap
$2.83B
Volume
1.00
52W High
$47.32
52W Low
$22.61
PE Ratio
108.12
VCYT Fundamentals
Price
$35.97
Prev Close
$36.73
Open
$36.90
50D MA
$33.03
Beta
1.69
Avg. Volume
1M
EPS (Annual)
$0.3088
P/B
2.32
Rev/Employee
$540,975.73
Loading...
Loading...
News
all
press releases
ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates
Integer Holdings posts strong Q3 results with earnings and revenue beat, but shares plunge on a softer 2026 growth outlook.
Zacks·4d ago
News Placeholder
More News
News Placeholder
ISRG Stock Gains on Q3 Earnings & Revenue Beat, Gross Margin Declines
Intuitive Surgical's shares jump 17% after Q3 earnings and revenues beat expectations, fueled by surging da Vinci 5 placements and strong global procedure growth.
Zacks·6d ago
News Placeholder
Boston Scientific Beats on Q3 Earnings, Raises 2025 View, Stock Up
BSX posts strong Q3 with 19% EPS growth, lifts 2025 sales and EPS outlook as shares edge higher.
Zacks·6d ago
News Placeholder
Thermo Fisher's Q3 Earnings & Revenues Top Estimates, Stock Climbs
TMO delivers robust Q3 results, fueled by margin growth, new launches and AI-focused strategic initiatives.
Zacks·6d ago
News Placeholder
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Zacks·6d ago
News Placeholder
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.
Zacks·7d ago
News Placeholder
Veracyte (VCYT) Crossed Above the 20-Day Moving Average: What That Means for Investors
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Zacks·12d ago
News Placeholder
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday...
Business Wire·13d ago
News Placeholder
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.
Zacks·13d ago
News Placeholder
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Zacks·21d ago

Latest VCYT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.